<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;ff=20250402082242&amp;fc=20230708114047&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;ff=20250402082242&amp;fc=20230708114047&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 02 Apr 2025 12:22:44 +0000</lastbuilddate>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>The Year in Cardiovascular Medicine 2024: the top 10 papers in interventional cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40171771/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402082242&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 2:ehaf106. doi: 10.1093/eurheartj/ehaf106. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40171771/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402082242&v=2.18.0.post9+e462414">40171771</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf106>10.1093/eurheartj/ehaf106</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40171771</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Emanuele Barbato</dc:creator>
<dc:creator>Tommaso Gori</dc:creator>
<dc:creator>Margaret McEntegart</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The Year in Cardiovascular Medicine 2024: the top 10 papers in interventional cardiology</dc:title>
<dc:identifier>pmid:40171771</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf106</dc:identifier>
</item>
<item>
<title>EMA601 and glenzocimab: two glycoprotein VI inhibitory Fabs with different potency</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40171679/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402082242&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 2:ehaf162. doi: 10.1093/eurheartj/ehaf162. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40171679/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402082242&v=2.18.0.post9+e462414">40171679</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf162>10.1093/eurheartj/ehaf162</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40171679</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Bernhard Nieswandt</dc:creator>
<dc:creator>David Stegner</dc:creator>
<dc:creator>Stefano Navarro</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>EMA601 and glenzocimab: two glycoprotein VI inhibitory Fabs with different potency</dc:title>
<dc:identifier>pmid:40171679</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf162</dc:identifier>
</item>
<item>
<title>European Research Council-funded grant: the embryonic obesogenic environment and cardiovascular diseases</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40171678/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402082242&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 2:ehaf141. doi: 10.1093/eurheartj/ehaf141. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40171678/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402082242&v=2.18.0.post9+e462414">40171678</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf141>10.1093/eurheartj/ehaf141</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40171678</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Romy Gaillard</dc:creator>
<dc:creator>Vincent W V Jaddoe</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>European Research Council-funded grant: the embryonic obesogenic environment and cardiovascular diseases</dc:title>
<dc:identifier>pmid:40171678</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf141</dc:identifier>
</item>
<item>
<title>Leaders in cardiology: Molly Stevens</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40171674/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402082242&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 2:ehaf140. doi: 10.1093/eurheartj/ehaf140. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40171674/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402082242&v=2.18.0.post9+e462414">40171674</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf140>10.1093/eurheartj/ehaf140</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40171674</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Judith Ozkan</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Leaders in cardiology: Molly Stevens</dc:title>
<dc:identifier>pmid:40171674</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf140</dc:identifier>
</item>
<item>
<title>European Research Council-funded grant: maintenance of platelet homeostasis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40171672/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402082242&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 2:ehae881. doi: 10.1093/eurheartj/ehae881. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40171672/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402082242&v=2.18.0.post9+e462414">40171672</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae881>10.1093/eurheartj/ehae881</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40171672</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Dulce Papy-Garcia</dc:creator>
<dc:creator>Omer Dushek</dc:creator>
<dc:creator>Yotis A Senis</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>European Research Council-funded grant: maintenance of platelet homeostasis</dc:title>
<dc:identifier>pmid:40171672</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae881</dc:identifier>
</item>
<item>
<title>Critical medications in cardiology: strategic policy of the European Medicines Agency</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40171671/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402082242&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 2:ehaf134. doi: 10.1093/eurheartj/ehaf134. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40171671/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402082242&v=2.18.0.post9+e462414">40171671</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf134>10.1093/eurheartj/ehaf134</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40171671</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Dobromir Dobrev</dc:creator>
<dc:creator>Juan Tamargo</dc:creator>
<dc:creator>Piotr Szymański</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Critical medications in cardiology: strategic policy of the European Medicines Agency</dc:title>
<dc:identifier>pmid:40171671</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf134</dc:identifier>
</item>
<item>
<title>Australia: challenges and opportunities for cardiologists</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40171664/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402082242&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 2:ehaf136. doi: 10.1093/eurheartj/ehaf136. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40171664/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402082242&v=2.18.0.post9+e462414">40171664</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf136>10.1093/eurheartj/ehaf136</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40171664</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Judith Ozkan</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Australia: challenges and opportunities for cardiologists</dc:title>
<dc:identifier>pmid:40171664</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf136</dc:identifier>
</item>
<item>
<title>European Research Council-funded grant: long non-coding RNA in adipocytes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40171663/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402082242&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 2:ehaf129. doi: 10.1093/eurheartj/ehaf129. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40171663/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402082242&v=2.18.0.post9+e462414">40171663</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf129>10.1093/eurheartj/ehaf129</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40171663</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Alastair G Kerr</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>European Research Council-funded grant: long non-coding RNA in adipocytes</dc:title>
<dc:identifier>pmid:40171663</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf129</dc:identifier>
</item>
<item>
<title>Glycoprotein VI inhibitors: glenzocimab and EMA601 two inhibitory Fabs</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40171661/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402082242&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 2:ehaf160. doi: 10.1093/eurheartj/ehaf160. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40171661/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402082242&v=2.18.0.post9+e462414">40171661</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf160>10.1093/eurheartj/ehaf160</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40171661</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Pierre H Mangin</dc:creator>
<dc:creator>Martine Jandrot-Perrus</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Glycoprotein VI inhibitors: glenzocimab and EMA601 two inhibitory Fabs</dc:title>
<dc:identifier>pmid:40171661</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf160</dc:identifier>
</item>
<item>
<title>PCSK9 Regulates Cardiac Mitochondrial Cholesterol by Promoting TSPO Degradation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40171648/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402082242&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These findings indicate that PCSK9 regulates mitochondrial cholesterol levels by modulating the TSPO degradation in the heart. Modulation of mitochondrial cholesterol by targeting TSPO may be a promising therapeutic approach for heart failure.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Apr 2. doi: 10.1161/CIRCRESAHA.124.325629. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cholesterol is critical for mitochondrial membrane structure and function. Given the emergence of mitochondria as a key factor in the pathogenesis of heart failure, mitochondrial cholesterol homeostasis may be crucial for maintaining mitochondrial properties and thus cardiac function. We previously showed that CM-<i>Pcsk9</i><sup>-/-</sup> mice (mice with cardiomyocyte-specific deletion of PCSK9 [proprotein convertase subtilisin-kexin type 9]) have impaired cardiomyocyte mitochondrial bioenergetics and heart function, paralleled by cardiomyocyte mitochondrial cholesterol accumulation and an increased number of mitochondria-endoplasmic reticulum contacts. However, the mechanisms linking PCSK9 to mitochondrial cholesterol homeostasis remain unclear. We hypothesized that PCSK9 acts on proteins involved in mitochondrial cholesterol trafficking in the heart to maintain cardiac mitochondrial function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: By performing RNA sequencing and immunoblot on CM-<i>Pcsk9</i><sup>-/-</sup> and CM-<i>Pcsk9</i><sup>+/+</sup> mouse hearts, we showed that TSPO (translocator protein) was increased by <i>Pcsk9</i> deficiency. To investigate the relationship between <i>TSPO</i> levels and heart function in humans, we compared the transcriptome of human left ventricles with high versus low <i>TSPO</i> levels. We used H9c2 (a rat cardiomyoblast cell line) cardiomyocytes to explore the mechanism linking PCSK9/TSPO to mitochondrial cholesterol content and function. The impact of reduced TSPO levels on cardiac function and mitochondrial oxidation in CM-<i>Pcsk9</i><sup>-/-</sup> mice was tested using adeno-associated virus serotype 9 short hairpin TSPO.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Both gene and protein levels of TSPO, a mitochondrial protein involved in cholesterol transport, were increased in CM-<i>Pcsk9</i><sup>-/-</sup> mouse hearts. Transcriptome analysis showed that high <i>TSPO</i> expression in human left ventricles was associated with impaired mitochondrial and cardiac function. We showed that PCSK9 induced TSPO degradation through a proteasomal mechanism that occurs in cardiomyocytes but not hepatocytes and contributes to maintaining normal mitochondrial cholesterol composition and function. At the molecular level, endoplasmic reticulum-resident PCSK9 interacted with GRP78, reducing GRP78-TSPO interactions and leading to TSPO misfolding and degradation by the ubiquitin-proteasome pathway. Importantly, gene therapy-induced downregulation of TSPO in CM-<i>Pcsk9</i><sup>-</sup><sup>/</sup><sup>-</sup> mice prevented mitochondrial cholesterol accumulation and improved cardiac function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings indicate that PCSK9 regulates mitochondrial cholesterol levels by modulating the TSPO degradation in the heart. Modulation of mitochondrial cholesterol by targeting TSPO may be a promising therapeutic approach for heart failure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40171648/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402082242&v=2.18.0.post9+e462414">40171648</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325629>10.1161/CIRCRESAHA.124.325629</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40171648</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Marion Laudette</dc:creator>
<dc:creator>Malin Lindbom</dc:creator>
<dc:creator>Mathieu Cinato</dc:creator>
<dc:creator>Per-Olof Bergh</dc:creator>
<dc:creator>Kristina Skålén</dc:creator>
<dc:creator>Arif Muhammad</dc:creator>
<dc:creator>Azra Miljanovic</dc:creator>
<dc:creator>Tomasz Czuba</dc:creator>
<dc:creator>Rosie Perkins</dc:creator>
<dc:creator>J Gustav Smith</dc:creator>
<dc:creator>Frank Lezoualc'h</dc:creator>
<dc:creator>Malin C Levin</dc:creator>
<dc:creator>Jan Borén</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>PCSK9 Regulates Cardiac Mitochondrial Cholesterol by Promoting TSPO Degradation</dc:title>
<dc:identifier>pmid:40171648</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325629</dc:identifier>
</item>
<item>
<title>Optimizing stem cell infusion timing in the prevention of acute graft-versus-host disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40168995/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402082242&amp;v=2.18.0.post9+e462414
      <description>Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a cornerstone treatment for a broad spectrum of malignant and nonmalignant hematological disorders. However, the success of allo-HSCT is often overshadowed by acute graft-versus-host disease (aGVHD), a life-threatening complication. Here, we show in patients and murine models that the circadian timing of stem cell infusion dictates the development of aGVHD. Early-infused patients exhibit a significantly lower incidence and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Mar 27:S0092-8674(25)00295-8. doi: 10.1016/j.cell.2025.03.022. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a cornerstone treatment for a broad spectrum of malignant and nonmalignant hematological disorders. However, the success of allo-HSCT is often overshadowed by acute graft-versus-host disease (aGVHD), a life-threatening complication. Here, we show in patients and murine models that the circadian timing of stem cell infusion dictates the development of aGVHD. Early-infused patients exhibit a significantly lower incidence and severity of aGVHD, as well as improved survival. We observed time-of-day variations in the levels of cytokines, especially IL-1α, which controls donor T cell responses after transplantation. The levels of IL-1α in patients were strongly associated with the development of aGVHD. Furthermore, preclinical results showed that the administration of IL-1α neutralizing antibodies markedly alleviated aGVHD and increased survival. Our study suggests that scheduling stem cell infusions early in the day could be a simple yet transformative intervention for preventing aGVHD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40168995/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402082242&v=2.18.0.post9+e462414">40168995</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.03.022>10.1016/j.cell.2025.03.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40168995</guid>
<pubDate>Tue, 01 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Yiwen Hou</dc:creator>
<dc:creator>Yue Wu</dc:creator>
<dc:creator>Yang Cao</dc:creator>
<dc:creator>Xiaoxia Hu</dc:creator>
<dc:creator>Yuqian Sun</dc:creator>
<dc:creator>Hongmei Wang</dc:creator>
<dc:creator>Liang Wang</dc:creator>
<dc:creator>Jialin Zhou</dc:creator>
<dc:creator>Zhonglin Zhang</dc:creator>
<dc:creator>Zhiwei Liu</dc:creator>
<dc:creator>Baolin Tang</dc:creator>
<dc:creator>Kaidi Song</dc:creator>
<dc:creator>Guangyu Sun</dc:creator>
<dc:creator>Wen Gao</dc:creator>
<dc:creator>Tianqi Zheng</dc:creator>
<dc:creator>Ping Wu</dc:creator>
<dc:creator>Weiwei Wu</dc:creator>
<dc:creator>Dapeng Ju</dc:creator>
<dc:creator>Xiaoyu Zhu</dc:creator>
<dc:creator>Cheng Zhan</dc:creator>
<dc:date>2025-04-01</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Optimizing stem cell infusion timing in the prevention of acute graft-versus-host disease</dc:title>
<dc:identifier>pmid:40168995</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.03.022</dc:identifier>
</item>
<item>
<title>Global analysis of protein turnover dynamics in single cells</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40168994/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402082242&amp;v=2.18.0.post9+e462414
      <description>Single-cell proteomics (SCPs) has advanced significantly, yet it remains largely unidimensional, focusing primarily on protein abundances. In this study, we employed a pulsed stable isotope labeling by amino acids in cell culture (pSILAC) approach to simultaneously analyze protein abundance and turnover in single cells (SC-pSILAC). Using a state-of-the-art SCP workflow, we demonstrated that two SILAC labels are detectable from ∼4,000 proteins in single HeLa cells recapitulating known biology. We...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Mar 26:S0092-8674(25)00275-2. doi: 10.1016/j.cell.2025.03.002. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Single-cell proteomics (SCPs) has advanced significantly, yet it remains largely unidimensional, focusing primarily on protein abundances. In this study, we employed a pulsed stable isotope labeling by amino acids in cell culture (pSILAC) approach to simultaneously analyze protein abundance and turnover in single cells (SC-pSILAC). Using a state-of-the-art SCP workflow, we demonstrated that two SILAC labels are detectable from ∼4,000 proteins in single HeLa cells recapitulating known biology. We performed a large-scale time-series SC-pSILAC analysis of undirected differentiation of human induced pluripotent stem cells (iPSCs) encompassing 6 sampling times over 2 months and analyzed >;1,000 cells. Protein turnover dynamics highlighted differentiation-specific co-regulation of protein complexes with core histone turnover, discriminating dividing and non-dividing cells. Lastly, correlating cell diameter with the abundance of individual proteins showed that histones and some cell-cycle proteins do not scale with cell size. The SC-pSILAC method provides a multidimensional view of protein dynamics in single-cell biology.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40168994/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402082242&v=2.18.0.post9+e462414">40168994</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.03.002>10.1016/j.cell.2025.03.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40168994</guid>
<pubDate>Tue, 01 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Pierre Sabatier</dc:creator>
<dc:creator>Maico Lechner</dc:creator>
<dc:creator>Ulises H Guzmán</dc:creator>
<dc:creator>Christian M Beusch</dc:creator>
<dc:creator>Xinlei Zeng</dc:creator>
<dc:creator>Longteng Wang</dc:creator>
<dc:creator>Fabiana Izaguirre</dc:creator>
<dc:creator>Anjali Seth</dc:creator>
<dc:creator>Olga Gritsenko</dc:creator>
<dc:creator>Sergey Rodin</dc:creator>
<dc:creator>Karl-Henrik Grinnemo</dc:creator>
<dc:creator>Zilu Ye</dc:creator>
<dc:creator>Jesper V Olsen</dc:creator>
<dc:date>2025-04-01</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Global analysis of protein turnover dynamics in single cells</dc:title>
<dc:identifier>pmid:40168994</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.03.002</dc:identifier>
</item>
<item>
<title>Mechanism of DNA capture by the MukBEF SMC complex and its inhibition by a viral DNA mimic</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40168993/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402082242&amp;v=2.18.0.post9+e462414
      <description>Ring-like structural maintenance of chromosome (SMC) complexes are crucial for genome organization and operate through mechanisms of DNA entrapment and loop extrusion. Here, we explore the DNA loading process of the bacterial SMC complex MukBEF. Using cryoelectron microscopy (cryo-EM), we demonstrate that ATP binding opens one of MukBEF's three potential DNA entry gates, exposing a DNA capture site that positions DNA at the open neck gate. We discover that the gp5.9 protein of bacteriophage T7...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Mar 27:S0092-8674(25)00259-4. doi: 10.1016/j.cell.2025.02.032. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Ring-like structural maintenance of chromosome (SMC) complexes are crucial for genome organization and operate through mechanisms of DNA entrapment and loop extrusion. Here, we explore the DNA loading process of the bacterial SMC complex MukBEF. Using cryoelectron microscopy (cryo-EM), we demonstrate that ATP binding opens one of MukBEF's three potential DNA entry gates, exposing a DNA capture site that positions DNA at the open neck gate. We discover that the gp5.9 protein of bacteriophage T7 blocks this capture site by DNA mimicry, thereby preventing DNA loading and inactivating MukBEF. We propose a comprehensive and unidirectional loading mechanism in which DNA is first captured at the complex's periphery and then ingested through the DNA entry gate, powered by a single cycle of ATP hydrolysis. These findings illuminate a fundamental aspect of how ubiquitous DNA organizers are primed for genome maintenance and demonstrate how this process can be disrupted by viruses.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40168993/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402082242&v=2.18.0.post9+e462414">40168993</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.02.032>10.1016/j.cell.2025.02.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40168993</guid>
<pubDate>Tue, 01 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Frank Bürmann</dc:creator>
<dc:creator>Bryony Clifton</dc:creator>
<dc:creator>Sophie Koekemoer</dc:creator>
<dc:creator>Oliver J Wilkinson</dc:creator>
<dc:creator>Dari Kimanius</dc:creator>
<dc:creator>Mark S Dillingham</dc:creator>
<dc:creator>Jan Löwe</dc:creator>
<dc:date>2025-04-01</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Mechanism of DNA capture by the MukBEF SMC complex and its inhibition by a viral DNA mimic</dc:title>
<dc:identifier>pmid:40168993</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.02.032</dc:identifier>
</item>
<item>
<title>Angiopoietin-Like 3 Antibody Therapy in Patients With Suboptimally Controlled Hyperlipidemia: A Phase 2 Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40167414/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402082242&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Based on standard lipid-lowering therapy, ANGPTL-3 inhibition with SHR-1918 further reduces LDL-C by 21.7% to 29.9% in patients at moderate or higher risk of ASCVD. These additional reductions are both dose and dosing frequency dependent. (Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemic; NCT06109831).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 24:S0735-1097(25)05339-2. doi: 10.1016/j.jacc.2025.03.008. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Angiopoietin-like 3 (ANGPTL-3) inhibits the activity of lipoprotein lipase and endothelial lipase, increasing both serum low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) levels. SHR-1918 is a fully human monoclonal antibody against ANGPTL-3.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The aim of this study was to assess the lipid-altering efficacy and safety of SHR-1918 in patients at moderate or higher risk of atherosclerotic cardiovascular disease (ASCVD) with suboptimally controlled hyperlipidemia.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A multicenter, randomized, double-blind, placebo-controlled, dose-escalation phase 2 study was designed to evaluate the effects of SHR-1918 in hypercholesterolemic patients, who did not achieve optimal LDL-C after 4 to 8 weeks of standard lipid-lowering therapies. A total of 333 patients were enrolled sequentially into 1 of 8 dose cohorts at a 4:1 (active/placebo) ratio. Patients received subcutaneous SHR-1918 at doses of 150, 300, or 600 mg every 4 weeks (Q4W), or SHR-1918 at a dose of 600 mg every 8 weeks (Q8W), alternating with placebo for a total treatment period of 16 weeks. The extension treatment included subcutaneous SHR-1918 at a dose of 150, 300, or 600 mg Q4W over 36 weeks, or SHR-1918 a dose of 600 mg Q8W over 40 weeks and then followed for safety. Prespecified endpoints included percentage change from baseline in LDL-C and TG. Safety was assessed with laboratory test results and by the incidence and severity of adverse events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: SHR-1918 demonstrated a clear dose-response relationship with respect to percentage LDL-C lowering for both Q4W and Q8W administration: 21.7%, 27.3%, and 29.9% with 150, 300, and 600 mg Q4W compared with placebo, respectively, and 22.5% with 600 mg Q8W compared with placebo. SHR-1918 also substantially reduced TG, non-high-density lipoprotein cholesterol, apolipoprotein B, and apolipoprotein A1, with a better achievement of LDL-C targets. SHR-1918 was generally well-tolerated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Based on standard lipid-lowering therapy, ANGPTL-3 inhibition with SHR-1918 further reduces LDL-C by 21.7% to 29.9% in patients at moderate or higher risk of ASCVD. These additional reductions are both dose and dosing frequency dependent. (Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemic; NCT06109831).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40167414/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402082242&v=2.18.0.post9+e462414">40167414</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.03.008>10.1016/j.jacc.2025.03.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40167414</guid>
<pubDate>Tue, 01 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Xiaojie Xie</dc:creator>
<dc:creator>Xiaoxia Shi</dc:creator>
<dc:creator>Yuming Zhang</dc:creator>
<dc:creator>Shuhong Su</dc:creator>
<dc:creator>Chenyan Jiang</dc:creator>
<dc:creator>Liu Miao</dc:creator>
<dc:creator>Junkui Wang</dc:creator>
<dc:creator>Daoquan Peng</dc:creator>
<dc:creator>Lingchun Lv</dc:creator>
<dc:creator>Xiaohong Chai</dc:creator>
<dc:creator>Suxin Luo</dc:creator>
<dc:creator>Yang Zheng</dc:creator>
<dc:creator>Shan Huang</dc:creator>
<dc:creator>Dan Zhu</dc:creator>
<dc:creator>Shangshang Liao</dc:creator>
<dc:creator>Meng Ren</dc:creator>
<dc:creator>Xiaohong Gao</dc:creator>
<dc:creator>Haibo Yang</dc:creator>
<dc:creator>Hao Zhou</dc:creator>
<dc:creator>Yuquan He</dc:creator>
<dc:creator>Yajun Han</dc:creator>
<dc:creator>Jiahong Xu</dc:creator>
<dc:creator>Lin Zhang</dc:creator>
<dc:creator>Laijing Du</dc:creator>
<dc:creator>Zhuhua Yao</dc:creator>
<dc:creator>Jianlong Sheng</dc:creator>
<dc:creator>Xiaoping Peng</dc:creator>
<dc:creator>Xiaowen Chen</dc:creator>
<dc:creator>Juxiang Li</dc:creator>
<dc:creator>Jie Mi</dc:creator>
<dc:creator>Qiang Lu</dc:creator>
<dc:creator>Hongju Wang</dc:creator>
<dc:creator>Zheng Shen</dc:creator>
<dc:creator>Zhilin Zhao</dc:creator>
<dc:creator>Feng Gao</dc:creator>
<dc:creator>Chao Lv</dc:creator>
<dc:creator>Min Zhu</dc:creator>
<dc:creator>Ying Zhu</dc:creator>
<dc:creator>Jian'an Wang</dc:creator>
<dc:date>2025-04-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Angiopoietin-Like 3 Antibody Therapy in Patients With Suboptimally Controlled Hyperlipidemia: A Phase 2 Study</dc:title>
<dc:identifier>pmid:40167414</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.03.008</dc:identifier>
</item>
<item>
<title>An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: The PURSUIT Randomized Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40167413/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402082242&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: AZD0780 demonstrated robust, dose-dependent reductions in LDL-C with a favorable safety and tolerability profile supporting further development of this once daily, oral treatment. (A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia [PURSUIT]; NCT06173570).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 27:S0735-1097(25)05907-8. doi: 10.1016/j.jacc.2025.03.499. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Most patients at high-risk for cardiovascular events do not achieve lipid goals advocated by American College of Cardiology/American Heart Association (ACC/AHA) guidelines despite the wide availability of lipid-lowering therapy. AZD0780 is a novel, oral, small molecule inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) in development as a once-daily treatment for hypercholesterolemia.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The phase 2 randomized, double-blind, placebo-controlled, multicenter PURSUIT trial evaluated the efficacy and safety of AZD0780 in patients with hypercholesterolemia already on background moderate-to-high-intensity statin treatment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Eligible study patients had a fasting low-density lipoprotein cholesterol (LDL-C) level of ≥70 mg/dL (1.8 mmol/L) and &lt;190 mg/dL (4.9 mmol/L), and triglycerides &lt;400 mg/dL on stable dose of moderate- or high-intensity statins, as defined by ACC/AHA or local guidelines, with or without ezetimibe at baseline. The study randomized patients 1:1:1:1:1 to receive AZD0780 1, 3, 10, or 30 mg, or matching placebo, oral once daily, for 12 weeks. The primary efficacy endpoint was percent change of LDL-C from baseline to week 12. Safety and tolerability evaluations included the number of adverse events, vital signs, electrocardiograms, and laboratory assessments.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In total, the study randomized 428 patients, of whom 426 started treatment. Patients were 52.1% male, with an average age of 62.4 ± 7.6 years. At week 12, compared with baseline, the placebo-corrected difference in least squares mean percent change of LDL-C for AZD0780 1, 3, 10, and 30 mg vs placebo was -35.3% (95% CI: -43.6% to -26.9%), -37.9% (95% CI:-46.3% to -29.5%), -45.2% (95% CI: -53.5% to -36.9%), and -50.7% (95% CI: -59.0% to -42.4%), respectively. Baseline statin use, moderate vs high intensity, did not alter AZD0780 efficacy. The proportion of patients reaching the ACC/AHA guideline LDL-C goal for high-risk patients increased in a dose-proportional manner. Adverse events compared similarly between the total AZD0780 treatment group (38.2%) and placebo (32.6%).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: AZD0780 demonstrated robust, dose-dependent reductions in LDL-C with a favorable safety and tolerability profile supporting further development of this once daily, oral treatment. (A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia [PURSUIT]; NCT06173570).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40167413/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402082242&v=2.18.0.post9+e462414">40167413</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.03.499>10.1016/j.jacc.2025.03.499</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40167413</guid>
<pubDate>Tue, 01 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Michael J Koren</dc:creator>
<dc:creator>Rick B Vega</dc:creator>
<dc:creator>Nikhil Agrawal</dc:creator>
<dc:creator>Yuejia Xu</dc:creator>
<dc:creator>April M Barbour</dc:creator>
<dc:creator>Hongtao Yu</dc:creator>
<dc:creator>Emelie Wallerstedt</dc:creator>
<dc:creator>Debra Carter</dc:creator>
<dc:creator>Jessica Middlemiss</dc:creator>
<dc:creator>Lee Twaddle</dc:creator>
<dc:creator>Michael C McCarthy</dc:creator>
<dc:creator>Jaya B Rosenmeier</dc:creator>
<dc:date>2025-04-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: The PURSUIT Randomized Trial</dc:title>
<dc:identifier>pmid:40167413</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.03.499</dc:identifier>
</item>
<item>
<title>Beyond LDL: Targeting ANGPTL3 to Reduce Residual Cardiovascular Risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40167412/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402082242&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 24:S0735-1097(25)05927-3. doi: 10.1016/j.jacc.2025.03.502. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40167412/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402082242&v=2.18.0.post9+e462414">40167412</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.03.502>10.1016/j.jacc.2025.03.502</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40167412</guid>
<pubDate>Tue, 01 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Dirk J Blom</dc:creator>
<dc:creator>Daniel Gaudet</dc:creator>
<dc:date>2025-04-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Beyond LDL: Targeting ANGPTL3 to Reduce Residual Cardiovascular Risk</dc:title>
<dc:identifier>pmid:40167412</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.03.502</dc:identifier>
</item>
<item>
<title>Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40167249/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402082242&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: A single combined measure of LDL cholesterol, hsCRP, and Lp(a) among initially healthy European men and women was predictive of incident MACE during a 20-year period. These data replicate findings from a recent American cohort and strongly support universal screening for all three biomarkers in primary prevention.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 1:ehaf209. doi: 10.1093/eurheartj/ehaf209. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Recent data from a large American cohort of women strongly support universal one-time screening for LDL cholesterol, high-sensitivity C-reactive protein (hsCRP), and lipoprotein(a) [Lp(a)] in primary prevention. This study addresses the validity and generalizability of this novel primary prevention strategy in a large prospective European cohort of initially healthy men and women.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Plasma levels of LDL cholesterol, hsCRP, and Lp(a) were measured at study entry in 17 087 participants from the EPIC-Norfolk study who were subsequently followed over a period of 20 years for major adverse cardiovascular events (MACEs). Competing risk- and multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for incident MACE across quintiles of each biomarker and sought evidence of independent as well as additive effects over time were calculated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During the 20-year follow-up, a total of 3249 MACEs occurred. Increasing quintiles of baseline LDL cholesterol, hsCRP, and Lp(a) all predicted 20-year risks; the multivariable-adjusted HRs in a comparison of the top to bottom quintile were 1.78 (95% CI: 1.57-2.00) for LDL cholesterol, 1.55 (95% CI: 1.37-1.74) for hsCRP, and 1.19 (95% CI: 1.07-1.33) for Lp(a). Compared with individuals with no biomarker elevations, the multivariable-adjusted HRs for incident MACE were 1.33, 1.68, and 2.41 for those with one, two, or three biomarkers in the top quintile, respectively (all P &lt; .001). Each biomarker demonstrated independent contributions to overall risk and findings were consistent in analyses stratified by sex.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: A single combined measure of LDL cholesterol, hsCRP, and Lp(a) among initially healthy European men and women was predictive of incident MACE during a 20-year period. These data replicate findings from a recent American cohort and strongly support universal screening for all three biomarkers in primary prevention.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40167249/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402082242&v=2.18.0.post9+e462414">40167249</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf209>10.1093/eurheartj/ehaf209</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40167249</guid>
<pubDate>Tue, 01 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Jordan M Kraaijenhof</dc:creator>
<dc:creator>Nick S Nurmohamed</dc:creator>
<dc:creator>Ask T Nordestgaard</dc:creator>
<dc:creator>Laurens F Reeskamp</dc:creator>
<dc:creator>Erik S G Stroes</dc:creator>
<dc:creator>G Kees Hovingh</dc:creator>
<dc:creator>S Matthijs Boekholdt</dc:creator>
<dc:creator>Paul M Ridker</dc:creator>
<dc:date>2025-04-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study</dc:title>
<dc:identifier>pmid:40167249</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf209</dc:identifier>
</item>
<item>
<title>Learning from epidemiology: atrial fibrillation, peripheral artery disease, and twin pregnancy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40166867/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402082242&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 1;46(13):1173-1177. doi: 10.1093/eurheartj/ehaf138.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40166867/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402082242&v=2.18.0.post9+e462414">40166867</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf138>10.1093/eurheartj/ehaf138</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40166867</guid>
<pubDate>Tue, 01 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2025-04-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Learning from epidemiology: atrial fibrillation, peripheral artery disease, and twin pregnancy</dc:title>
<dc:identifier>pmid:40166867</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf138</dc:identifier>
</item>
<item>
<title>Lymphatic Endothelial Branched-Chain Amino Acid Catabolic Defects Undermine Cardiac Lymphatic Integrity and Drive HFpEF</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40166847/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402082242&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our study provides evidence that cardiac lymphatic disruption, driven by impaired BCAA catabolism in LECs, is a key factor contributing to HFpEF. These findings unravel the crucial role of BCAA catabolism in modulating lymphatic biology, and suggest that preserving cardiac lymphatic integrity may present a novel therapeutic strategy for HFpEF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr 1. doi: 10.1161/CIRCULATIONAHA.124.071741. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) has become the most prevalent type of heart failure, but effective treatments are lacking. Cardiac lymphatics play a crucial role in maintaining heart health by draining fluids and immune cells. However, their involvement in HFpEF remains largely unexplored.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We examined cardiac lymphatic alterations in mice with HFpEF with comorbid obesity and hypertension, and in heart tissues from patients with HFpEF. Using genetically engineered mouse models and various cellular and molecular techniques, we investigated the role of cardiac lymphatics in HFpEF and the underlying mechanisms.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In mice with HFpEF, cardiac lymphatics displayed substantial structural and functional anomalies, including decreased lymphatic endothelial cell (LEC) density, vessel fragmentation, reduced branch connections, and impaired capacity to drain fluids and immune cells. LEC numbers and marker expression levels were also decreased in heart tissues from patients with HFpEF. Stimulating lymphangiogenesis with an adeno-associated virus expressing an engineered variant of vascular endothelial growth factor C (VEGFC<sup>C156S</sup>) that selectively activates vascular endothelial growth factor receptor 3 (VEGFR3) in LECs restored cardiac lymphatic integrity and substantially alleviated HFpEF. Through discovery-driven approaches, defective branched-chain amino acid (BCAA) catabolism was identified as a predominant metabolic signature in HFpEF cardiac LECs. Overexpression of branched-chain ketoacid dehydrogenase kinase (encoded by the <i>Bckdk</i> gene), which inactivates branched-chain ketoacid dehydrogenase (the rate-limiting enzyme in BCAA catabolism), resulted in spontaneous lymphangiogenic defects in LECs. In mice, inducible <i>Bckdk</i> gene deletion in LECs to enhance their BCAA catabolism preserved cardiac lymphatic integrity and protected against HFpEF. BCAA catabolic defects caused ligand-independent phosphorylation of VEGFR3 in the cytoplasm by Src kinase, leading to lysosomal degradation of VEGFR3 instead of its trafficking to the cell membrane. Reduced VEGFR3 availability on the cell surface impeded downstream Akt (protein kinase B) activation, hindered glucose uptake and utilization, and inhibited lymphangiogenesis in LECs with BCAA catabolic defects.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our study provides evidence that cardiac lymphatic disruption, driven by impaired BCAA catabolism in LECs, is a key factor contributing to HFpEF. These findings unravel the crucial role of BCAA catabolism in modulating lymphatic biology, and suggest that preserving cardiac lymphatic integrity may present a novel therapeutic strategy for HFpEF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40166847/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402082242&v=2.18.0.post9+e462414">40166847</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071741>10.1161/CIRCULATIONAHA.124.071741</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40166847</guid>
<pubDate>Tue, 01 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Xiong Guo</dc:creator>
<dc:creator>Chong Huang</dc:creator>
<dc:creator>Ling Zhang</dc:creator>
<dc:creator>Guangyu Hu</dc:creator>
<dc:creator>Yunhui Du</dc:creator>
<dc:creator>Xiyao Chen</dc:creator>
<dc:creator>Fangfang Sun</dc:creator>
<dc:creator>Tongzheng Li</dc:creator>
<dc:creator>Zhe Cui</dc:creator>
<dc:creator>Congye Li</dc:creator>
<dc:creator>Yongzhen Guo</dc:creator>
<dc:creator>Wenjun Yan</dc:creator>
<dc:creator>Yunlong Xia</dc:creator>
<dc:creator>Shan Wang</dc:creator>
<dc:creator>Hui Liu</dc:creator>
<dc:creator>Zhiyuan Liu</dc:creator>
<dc:creator>Zhen Lin</dc:creator>
<dc:creator>Xinyi Wang</dc:creator>
<dc:creator>Zhengyang Wang</dc:creator>
<dc:creator>Fuyang Zhang</dc:creator>
<dc:creator>Ling Tao</dc:creator>
<dc:date>2025-04-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Lymphatic Endothelial Branched-Chain Amino Acid Catabolic Defects Undermine Cardiac Lymphatic Integrity and Drive HFpEF</dc:title>
<dc:identifier>pmid:40166847</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071741</dc:identifier>
</item>
<item>
<title>A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40166829/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402082242&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: For patients with acute heart failure and pleural effusion, a strategy of upfront routine thoracentesis in addition to standard medical therapy did not increase days alive out of the hospital for 90 days, all-cause mortality, or duration of index admission. The current findings lay the groundwork for future research to confirm the results.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr 1. doi: 10.1161/CIRCULATIONAHA.124.073521. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: TAP-IT (Thoracentesis to Alleviate Cardiac Pleural Effusion-Interventional Trial) investigated the effect of therapeutic thoracentesis in addition to standard medical therapy in patients with acute heart failure and sizeable pleural effusion.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This multicenter, unblinded, randomized controlled trial, conducted between August 31, 2021, and March 22, 2024, included patients with acute heart failure, left ventricular ejection fraction ≤45%, and non-negligible pleural effusion. Patients with very large effusions (more than two-thirds of the hemithorax) were excluded. Participants were randomly assigned 1:1 to upfront ultrasound-guided pleural pigtail catheter thoracentesis in addition to standard medical therapy or standard medical therapy alone. The primary outcome was days alive out of the hospital over the following 90 days; key secondary outcomes included length of admission and 90-day all-cause mortality. All outcomes were analyzed according to the intention-to-treat principle.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 135 patients (median age, 81 years [25th; 75th percentile, 75; 83]; 33% female; median left ventricular ejection fraction, 25% [25th; 75th percentile, 20%; 35%]) were randomized to either thoracentesis (n=68) or standard medical therapy (n=67). The thoracentesis group had a median of 84 days (77; 86) alive out of the hospital over the following 90 days compared with 82 days (73; 86) in the control group (<i>P</i>=0.42). The mortality rate was 13% in both groups, with no difference in survival probability (<i>P</i>=0.90). There were no differences in the duration of the index admission (control group median, 5 days [3; 8]; thoracentesis group median, 5 days [3; 7; <i>P</i>=0.69]). Major complications occurred in 1% of thoracenteses performed during the study period.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: For patients with acute heart failure and pleural effusion, a strategy of upfront routine thoracentesis in addition to standard medical therapy did not increase days alive out of the hospital for 90 days, all-cause mortality, or duration of index admission. The current findings lay the groundwork for future research to confirm the results.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05017753.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40166829/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402082242&v=2.18.0.post9+e462414">40166829</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.073521>10.1161/CIRCULATIONAHA.124.073521</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40166829</guid>
<pubDate>Tue, 01 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Signe Glargaard</dc:creator>
<dc:creator>Jakob Hartvig Thomsen</dc:creator>
<dc:creator>Christian Tuxen</dc:creator>
<dc:creator>Matias Greve Lindholm</dc:creator>
<dc:creator>Christian Axel Bang</dc:creator>
<dc:creator>Morten Schou</dc:creator>
<dc:creator>Kasper Iversen</dc:creator>
<dc:creator>Rasmus Vedby Rasmussen</dc:creator>
<dc:creator>Brian Bridal Løgstrup</dc:creator>
<dc:creator>Søren Vraa</dc:creator>
<dc:creator>Nis Stride</dc:creator>
<dc:creator>Ekim Seven</dc:creator>
<dc:creator>Anders Barasa</dc:creator>
<dc:creator>Marlene Tofterup</dc:creator>
<dc:creator>Dan Eik Høfsten</dc:creator>
<dc:creator>Kasper Rossing</dc:creator>
<dc:creator>Lars Køber</dc:creator>
<dc:creator>Finn Gustafsson</dc:creator>
<dc:creator>Jens Jakob Thune</dc:creator>
<dc:date>2025-04-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure</dc:title>
<dc:identifier>pmid:40166829</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.073521</dc:identifier>
</item>
<item>
<title>Olmesartan Restores &lt;em>;LMNA&lt;/em>; Function in Haploinsufficient Cardiomyocytes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40166828/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402082242&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In silico screening followed by in vitro validation with induced pluripotent stem cell-derived models can be an efficient approach to identifying repositionable therapies for monogenic cardiomyopathies.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr 1. doi: 10.1161/CIRCULATIONAHA.121.058621. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Gene mutations are responsible for a sizeable proportion of cases of heart failure. However, the number of patients with any specific mutation is small. Repositioning of existing US Food and Drug Administration-approved compounds to target specific mutations is a promising approach to efficient identification of new therapies for these patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The National Institutes of Health Library of Integrated Network-Based Cellular Signatures database was interrogated to identify US Food and Drug Administration-approved compounds that demonstrated the ability to reverse the transcriptional effects of <i>LMNA</i> knockdown. Top hits from this screening were validated in vitro with patient-specific induced pluripotent stem cell-derived cardiomyocytes combined with force measurement, gene expression profiling, electrophysiology, and protein expression analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Several angiotensin receptor blockers were identified from our in silico screen. Of these, olmesartan significantly elevated the expression of sarcomeric genes and rate and force of contraction and ameliorated arrhythmogenic potential. In addition, olmesartan exhibited the ability to reduce phosphorylation of extracellular signal-regulated kinase 1 in <i>LMNA</i>-mutant induced pluripotent stem cell-derived cardiomyocytes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In silico screening followed by in vitro validation with induced pluripotent stem cell-derived models can be an efficient approach to identifying repositionable therapies for monogenic cardiomyopathies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40166828/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402082242&v=2.18.0.post9+e462414">40166828</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.121.058621>10.1161/CIRCULATIONAHA.121.058621</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40166828</guid>
<pubDate>Tue, 01 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Eric J Kort</dc:creator>
<dc:creator>Nazish Sayed</dc:creator>
<dc:creator>Chun Liu</dc:creator>
<dc:creator>Gema Mondéjar-Parreño</dc:creator>
<dc:creator>Jens Forsberg</dc:creator>
<dc:creator>Emily Eugster</dc:creator>
<dc:creator>Sean M Wu</dc:creator>
<dc:creator>Joseph C Wu</dc:creator>
<dc:creator>Stefan Jovinge</dc:creator>
<dc:date>2025-04-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Olmesartan Restores &lt;em>;LMNA&lt;/em>; Function in Haploinsufficient Cardiomyocytes</dc:title>
<dc:identifier>pmid:40166828</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.121.058621</dc:identifier>
</item>





























</channel>
</rss>